Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised …

…, J Mootien, B Mourvillier, M Murris-Espin… - The Lancet infectious …, 2022 - thelancet.com
Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …

The EMBARC European Bronchiectasis Registry: protocol for an international observational study

…, G Rohde, M Murris-Espin… - ERJ open …, 2016 - Eur Respiratory Soc
Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no
approved therapies and few large-scale, representative epidemiological studies. The …

Real-life safety and effectiveness of lumacaftor–ivacaftor in patients with cystic fibrosis

…, L Mely, A Prevotat, M Murris-Espin… - American journal of …, 2020 - atsjournals.org
Rationale: Lumacaftor–ivacaftor is a CFTR (cystic fibrosis transmembrane conductance
regulator) modulator combination recently approved for patients with cystic fibrosis (CF) …

Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis

…, R Hamidfar, I Durieu, M Murris-Espin… - Journal of Cystic …, 2022 - Elsevier
Background Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients
with cystic fibrosis (CF) and advanced pulmonary disease, often leading to suspend the …

Mycobacteria–host interactions in human bronchiolar airway organoids

…, A Peixoto, C Bernard, M MurrisEspin… - Molecular …, 2022 - Wiley Online Library
Respiratory infections remain a major global health concern. Tuberculosis is one of the top
10 causes of death worldwide, while infections with Non‐Tuberculous Mycobacteria are …

Sleep quality and nocturnal hypoxaemia and hypercapnia in children and young adults with cystic fibrosis

…, PY Boelle, C Cracowski, M Murris-Espin… - Archives of disease in …, 2012 - adc.bmj.com
Objectives The aim of the study was to evaluate sleep quality and nocturnal gas exchange
in patients with cystic fibrosis (CF) and to assess if sleep quality and daytime lung function …

Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial

…, L Bassinet, M Murris-Espin… - European …, 2022 - Eur Respiratory Soc
Background In allergic bronchopulmonary aspergillosis (ABPA), prolonged nebulised
antifungal treatment may be a strategy for maintaining remission. Methods We performed a …

Using chest computed tomography and unsupervised machine learning for predicting and evaluating response to lumacaftor–ivacaftor in people with cystic fibrosis

…, C Marguet, C Belleguic, M Murris-Espin… - European …, 2022 - Eur Respiratory Soc
Objectives Lumacaftor–ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR)
modulator known to improve clinical status in people with cystic fibrosis (CF). The aim …

[HTML][HTML] Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis

…, S Leroy, R Nove-Josserand, M Murris-Espin… - Journal of Cystic …, 2009 - Elsevier
BACKGROUND: Nebulization times have been identified as an issue in patient compliance
with tobramycin solution for inhalation (TSI) therapy in cystic fibrosis (CF). METHODS: In this …

Numerical and experimental investigation of mucociliary clearance breakdown in cystic fibrosis

R Chatelin, D Anne-Archard, M Murris-Espin… - Journal of …, 2017 - Elsevier
The human tracheobronchial tree surface is covered with mucus. A healthy mucus is a
heterogeneous material flowing toward the esophagus and a major defense actor against local …